Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.46 |
| ▸ | P2RY10 | O00398 | 4/20 | 0.42 |
| ▸ | GPR174 | Q9BXC1 | 4/20 | 0.42 |
| ▸ | LAP3 | P28838 | 4/20 | 0.41 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.40 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.40 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL42675 | 1.00 | SLC7A5 (0.46) | SLC7A5P2RY10GPR174LAP3SLC1A3 | |
| SCHEMBL13308410 | 1.00 | SLC7A5 (0.46) | SLC7A5P2RY10GPR174LAP3SLC1A3 | |
| SCHEMBL27534147 | 0.98 | SLC7A5 (0.44) | SLC7A5P2RY10GPR174LAP3SLC1A3 | |
| Glycine SCHEMBL10277138 | 0.91 | P2RY10 (0.40) | SLC7A5P2RY10GPR174LAP3SLC1A3 | |
| SCHEMBL29687290 | 0.88 | LAP3 (0.35) | SLC7A5P2RY10GPR174LAP3 | |
| SCHEMBL12609432 | 0.85 | SLC7A5 (0.44) | SLC7A5P2RY10GPR174LAP3SLC1A3 | |
| Dexfosfoserine SCHEMBL6513515 | 0.85 | PGK1 (0.43) | P2RY10GPR174 | |
| SCHEMBL8934990 | 0.84 | GPR174 (0.44) | SLC7A5P2RY10GPR174LAP3SLC1A3 | |
| Glutamine SCHEMBL6864537 | 0.82 | ALOX15 (0.56) | P2RY10GPR174SLC1A3SLC1A2SLC1A1 | |
| SCHEMBL2232197 | 0.81 | SLC7A5 (0.44) | SLC7A5P2RY10GPR174LAP3SLC1A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 173 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024197259-A1 | TRANSCYTOTIC INTERCELLULAR GELATION ENABLES CELL SPHEROIDS | BRANDEIS UNIVERSITY (US) | 2024-09-26 | — | — | WO | claimed |
| US-20260146063-A1 | CYCLIC CELL PENETRATING PEPTIDES AND METHODS OF MAKING AND USING THEREOF | OHIO STATE INNOVATION FOUNDATION (US) | 2026-05-28 | — | — | US | disclosed |
| US-20260125426-A1 | CYCLIC CELL-PENETRATING PEPTIDES AND USES THEREOF | OHIO STATE INNOVATION FOUNDATION (US) | 2026-05-07 | — | — | US | disclosed |
| US-20260115301-A1 | INTRACELLULAR DELIVERY OF NUCLEIC ACIDS | OHIO STATE INNOVATION FOUNDATION (US) | 2026-04-30 | — | — | US | disclosed |
| EP-4717776-A2 | POLYPEPTIDE CONJUGATES FOR INTRACELLULAR DELIVERY OF NUCLEIC ACIDS | Ohio State Innovation Foundation (US) | 2026-04-01 | — | — | EP | disclosed |
| US-20260070948-A1 | CYCLIC CELL-PENETRATING PEPTIDES WITH CARGO | OHIO STATE INNOVATION FOUNDATION (US) | 2026-03-12 | — | — | US | disclosed |
| US-20260070947-A1 | CYCLIC CELL-PENETRATING PEPTIDE COMPOUNDS | OHIO STATE INNOVATION FOUNDATION (US) | 2026-03-12 | — | — | US | disclosed |
| EP-4706689-A2 | COMPOSITIONS FOR DELIVERY OF ANTISENSE COMPOUNDS | Entrada Therapeutics, Inc. (US) | 2026-03-11 | — | — | EP | disclosed |
| EP-4097145-B1 | REDUCTION OF ADSORPTION | LEUKOCARE AG (DE) | 2026-01-28 | — | — | EP | disclosed |
| US-20260008813-A1 | CELL-PENETRATING PEPTIDE COMPOUNDS | OHIO STATE INNOVATION FOUNDATION (US) | 2026-01-08 | — | — | US | disclosed |
| WO-2010112576-A1 | MEANS AND METHODS OF STERILIZATION OF BIOFUNCTIONAL COMPOSITIONS | LEUKOCARE AG (DE) | 2010-10-07 | — | — | WO | disclosed |
| EP-2236520-A1 | Stabilizing composition for immobilized biomolecules | LEUKOCARE AG (DE) | 2010-10-06 | — | — | EP | disclosed |
| EP-2084519-A2 | ADVANCED DRUG DEVELOPMENT AND MANUFACTURING | Los Alamos National Security, LLC (US) | 2009-08-05 | — | — | EP | disclosed |
| US-7521538-B2 | Crystal structure of the ternary complex of 14-3-3/Fusicoccin/PMA and methods for designing new herbicides | MAX-PLANCK-GESELLSCHAFT ZUR FOERDERUNG DER WISSENSCHAFTEN E.V. (DE) | 2009-04-21 | — | — | US | disclosed |
| WO-2008127291-A2 | ADVANCED DRUG DEVELOPMENT AND MANUFACTURING | LOS ALAMOS NATIONAL SECURITY, LLC (US) | 2008-10-23 | — | — | WO | disclosed |
| US-20080220441-A1 | Advanced drug development and manufacturing | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2008-09-11 | — | — | US | disclosed |
| US-20070287629-A1 | Crystal structure of the ternary complex of 14-3-3/fusicoccin/pma and methods for designing new herbicides | MAX-PLANCK-GESELLSCHAFT ZUR FOERDERUNG DER WISSENSCHAFTEN E.V. (DE) | 2007-12-13 | — | — | US | disclosed |
| WO-2007050673-A2 | CYCLIN DEPENDENT KINASE INHIBITORS | UNIVERSITY OF FLORIDA (US) | 2007-05-03 | — | — | WO | disclosed |
| EP-1599497-A2 | CRYSTAL STRUCTURE OF THE TERNARY COMPELEX OF 14-3-3, FUSICOCCIN, AND PLASMA MEMBRANE ATPASE AND METHODS FOR DESIGNING NEW HERBICIDES | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Berlin (DE) | 2005-11-30 | — | — | EP | disclosed |
| WO-2004075635-A2 | CRYSTAL STRUCTURE OF THE TERNARY COMPELEX OF 14-3-3, FUSICOCCIN AND PLASMA MEMBRANE ATPASE AND METHODS FOR DESIGNING NEW HERBICIDES | MAX-PLANCK-GESELLSCHAFT ZUR (DE) | 2004-09-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260115301-A1 | INTRACELLULAR DELIVERY OF NUCLEIC ACIDS | SLC7A1, SRM, SLC6A19 | SLC7A5 4/4885P2RY10 3907/4885GPR174 3874/4885 |
| US-20260146063-A1 | CYCLIC CELL PENETRATING PEPTIDES AND METHODS OF MAKING AND USING THEREOF | VIP, SLC7A1, SLC6A15 | SLC7A5 7/4885P2RY10 4095/4885GPR174 2518/4885 |
| US-20260125426-A1 | CYCLIC CELL-PENETRATING PEPTIDES AND USES THEREOF | SLC7A1, TAP1, SLC7A5 | SLC7A5 3/4885P2RY10 4260/4885GPR174 3443/4885 |
| US-20260070947-A1 | CYCLIC CELL-PENETRATING PEPTIDE COMPOUNDS | SLC7A1, SLC38A7, SLC6A19 | SLC7A5 4/4885P2RY10 3362/4885GPR174 3217/4885 |
| US-20260070948-A1 | CYCLIC CELL-PENETRATING PEPTIDES WITH CARGO | SLC7A1, SLC38A7, SLC6A19 | SLC7A5 13/4885P2RY10 2545/4885GPR174 3267/4885 |
| US-20260008813-A1 | CELL-PENETRATING PEPTIDE COMPOUNDS | SLC7A1, SLC38A7, SLC6A19 | SLC7A5 17/4885P2RY10 3213/4885GPR174 1920/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.